• 1. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 2. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528
• 3. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 4. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

Recent Advances in the Application of 2,6-Difluoropyridine-3-carbonitrile (CAS: 869557-17-5) in Chemical Biology and Pharmaceutical Research

2,6-Difluoropyridine-3-carbonitrile (CAS: 869557-17-5) has emerged as a key intermediate in the synthesis of novel bioactive compounds, particularly in the development of kinase inhibitors and other therapeutic agents. Recent studies have highlighted its versatility in medicinal chemistry, owing to its unique electronic properties and reactivity profile. This research brief aims to summarize the latest findings related to this compound, focusing on its synthetic applications, biological activities, and potential therapeutic implications.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers demonstrated the utility of 2,6-difluoropyridine-3-carbonitrile as a building block for the synthesis of selective JAK2 inhibitors. The compound's fluorine atoms and nitrile group were found to enhance binding affinity and metabolic stability, making it a promising candidate for the treatment of myeloproliferative disorders. The study reported a significant improvement in inhibitory potency (IC50 values in the low nanomolar range) compared to previous generations of inhibitors.

Another recent application was reported in ACS Chemical Biology, where 2,6-difluoropyridine-3-carbonitrile was incorporated into PROTAC (Proteolysis Targeting Chimera) molecules targeting BET proteins. The compound's ability to serve as a linker between the target-binding moiety and the E3 ligase-recruiting element was particularly noteworthy, demonstrating improved cellular permeability and degradation efficiency (DC50 values below 100 nM in multiple cancer cell lines).

From a synthetic chemistry perspective, a 2024 Nature Communications paper detailed an innovative Pd-catalyzed cross-coupling reaction using 2,6-difluoropyridine-3-carbonitrile as the starting material. The researchers achieved remarkable regioselectivity (greater than 95:5) in the functionalization of the pyridine ring, enabling the efficient synthesis of diverse compound libraries for high-throughput screening.

In the field of radiopharmaceuticals, 2,6-difluoropyridine-3-carbonitrile has shown promise as a precursor for 18F-labeled PET tracers. A recent study in the Journal of Nuclear Medicine reported the development of a novel tau protein imaging agent incorporating this scaffold, demonstrating excellent brain uptake and target specificity in preclinical models of Alzheimer's disease.

Despite these advances, challenges remain in the large-scale production and purification of 2,6-difluoropyridine-3-carbonitrile. Recent process chemistry studies have focused on optimizing synthetic routes to improve yield and reduce byproduct formation, with some success in achieving kilogram-scale production with greater than 90% purity.

Looking forward, the unique properties of 2,6-difluoropyridine-3-carbonitrile continue to inspire innovative applications in drug discovery. Ongoing research is exploring its potential in covalent inhibitor design, allosteric modulator development, and as a component of novel drug delivery systems. The compound's versatility and demonstrated biological activity suggest it will remain an important tool in medicinal chemistry for the foreseeable future.

• 3939-12-6(5-Cyano-2-fluoropyridine)
• 870065-73-9(2,5,6-Trifluoro-3-pyridinecarbonitrile)
• 111887-71-9(2-Fluoro-3,5-dimethylpyridine)
• 51991-35-6(4-Pyridinecarbonitrile,2,6-difluoro-)
• 261625-67-6(5-Cyano-2-fluoro-3-picoline)
• 3939-13-7(2-fluoropyridine-3-carbonitrile)
• 2369-18-8(2-Fluoro-3-picoline)
• 54957-80-1(2-Fluoro-6-methylnicotinonitrile)
• 3939-14-8(2-Fluoroisonicotinonitrile)
• 832735-44-1(Benzonitrile, 4-(6-fluoro-3-pyridinyl)-)